156 related articles for article (PubMed ID: 26190207)
1. Insights into the key interactions between human protein phosphatase 5 and cantharidin using molecular dynamics and site-directed mutagenesis bioassays.
Liu JY; Chen XE; Zhang YL
Sci Rep; 2015 Jul; 5():12359. PubMed ID: 26190207
[TBL] [Abstract][Full Text] [Related]
2. Interactions of cantharidin-like inhibitors with human protein phosphatase-5 in a Mg
Assis LC; de Castro AA; Prandi IG; Mancini DT; de Giacoppo JOS; Savedra RML; de Assis TM; Carregal JB; da Cunha EFF; Ramalho TC
J Mol Model; 2018 Oct; 24(10):303. PubMed ID: 30280322
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Chattopadhyay D; Swingle MR; Salter EA; Wood E; D'Arcy B; Zivanov C; Abney K; Musiyenko A; Rusin SF; Kettenbach A; Yet L; Schroeder CE; Golden JE; Dunham WH; Gingras AC; Banerjee S; Forbes D; Wierzbicki A; Honkanen RE
Biochem Pharmacol; 2016 Jun; 109():14-26. PubMed ID: 27002182
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin.
Bertini I; Calderone V; Fragai M; Luchinat C; Talluri E
J Med Chem; 2009 Aug; 52(15):4838-43. PubMed ID: 19601647
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
[TBL] [Abstract][Full Text] [Related]
6. Ro 90-7501 inhibits PP5 through a novel, TPR-dependent mechanism.
Hong TJ; Park K; Choi EW; Hahn JS
Biochem Biophys Res Commun; 2017 Jan; 482(2):215-220. PubMed ID: 27840051
[TBL] [Abstract][Full Text] [Related]
7. Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma.
Hu MH; Huang TT; Chao TI; Chen LJ; Chen YL; Tsai MH; Liu CY; Kao JH; Chen KF
Liver Int; 2018 Dec; 38(12):2248-2259. PubMed ID: 29797403
[TBL] [Abstract][Full Text] [Related]
8. Cantharidin impedes the activity of protein serine/threonine phosphatase in Plutella xylostella.
Chen X; Liu J; Zhang Y
Mol Biosyst; 2014 Feb; 10(2):240-50. PubMed ID: 24253262
[TBL] [Abstract][Full Text] [Related]
9. Exploration of new drug-like inhibitors for serine/threonine protein phosphatase 5 of Plasmodium falciparum: a docking and simulation study.
Gupta S; Jadaun A; Kumar H; Raj U; Varadwaj PK; Rao AR
J Biomol Struct Dyn; 2015; 33(11):2421-41. PubMed ID: 25967133
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).
Swingle MR; Honkanen RE
Assay Drug Dev Technol; 2014 Oct; 12(8):481-96. PubMed ID: 25383722
[TBL] [Abstract][Full Text] [Related]
12. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Ren Y; Kinghorn AD
Bioorg Med Chem; 2021 Feb; 32():116012. PubMed ID: 33454654
[TBL] [Abstract][Full Text] [Related]
13. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode.
Baba Y; Hirukawa N; Sodeoka M
Bioorg Med Chem; 2005 Sep; 13(17):5164-70. PubMed ID: 15951185
[TBL] [Abstract][Full Text] [Related]
14. Identification and biochemical characterization of protein phosphatase 5 from the cantharidin-producing blister beetle, Epicauta chinensis.
Chen X; Lü S; Zhang Y
Int J Mol Sci; 2013 Dec; 14(12):24501-13. PubMed ID: 24351830
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking and dynamic simulation evaluation of Rohinitib - Cantharidin based novel HSF1 inhibitors for cancer therapy.
Agarwal T; Annamalai N; Khursheed A; Maiti TK; Arsad HB; Siddiqui MH
J Mol Graph Model; 2015 Sep; 61():141-9. PubMed ID: 26245696
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin).
Baba Y; Hirukawa N; Tanohira N; Sodeoka M
J Am Chem Soc; 2003 Aug; 125(32):9740-9. PubMed ID: 12904040
[TBL] [Abstract][Full Text] [Related]
17. Characterization of protein phosphatase 5 from three lepidopteran insects: Helicoverpa armigera, Mythimna separata and Plutella xylostella.
Chen X; Lü S; Zhang Y
PLoS One; 2014; 9(5):e97437. PubMed ID: 24823652
[TBL] [Abstract][Full Text] [Related]
18. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
McCluskey A; Walkom C; Bowyer MC; Ackland SP; Gardiner E; Sakoff JA
Bioorg Med Chem Lett; 2001 Nov; 11(22):2941-6. PubMed ID: 11677131
[TBL] [Abstract][Full Text] [Related]
19. Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?
McCuskey A; Keane MA; Mudgee LM; Sim AT; Sakoff J; Quinn RJ
Eur J Med Chem; 2000 Oct; 35(10):957-64. PubMed ID: 11121622
[TBL] [Abstract][Full Text] [Related]
20. Selective activators of protein phosphatase 5 target the auto-inhibitory mechanism.
Haslbeck V; Drazic A; Eckl JM; Alte F; Helmuth M; Popowicz G; Schmidt W; Braun F; Weiwad M; Fischer G; Gemmecker G; Sattler M; Striggow F; Groll M; Richter K
Biosci Rep; 2015 Apr; 35(3):. PubMed ID: 26182372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
